TRCT
STML

Tower Research Capital (TRC)’s Stemline Therapeutics, Inc. STML Stock Holding History

Tower Research Capital (TRC)’s Portfolio STML Stock Details STML Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		– Sell
-7,115
Closed -$74K – 4813
2019
Q3 		$74K Buy
7,115
+5,583
+364% +$73K 0.01% 1533
2019
Q2 		$23K Buy
+1,532
New +$22.2K ﹤0.01% 2104
2018
Q4 		– Sell
-444
Closed -$7K – 4639
2018
Q3 		$7K Sell
444
-1,558
-78% -$25K ﹤0.01% 2997
2018
Q2 		$32K Buy
+2,002
New +$35.7K ﹤0.01% 2137
2018
Q1 		– Sell
-584
Closed -$9K – 4136
2017
Q4 		$9K Sell
584
-2,325
-80% -$31.1K ﹤0.01% 2646
2017
Q3 		$33K Buy
2,909
+2,839
+4,056% +$26.7K ﹤0.01% 2372
2017
Q2 		$1K Sell
70
-1,681
-96% -$14K ﹤0.01% 2566
2017
Q1 		$15K Buy
1,751
+1,294
+283% +$11.8K ﹤0.01% 1509
2016
Q4 		$5K Buy
+457
New +$5.53K ﹤0.01% 3099
2016
Q3 		– Sell
-1,015
Closed -$7K – 4855
2016
Q2 		$7K Sell
1,015
-4,192
-81% -$26.5K ﹤0.01% 3196
2016
Q1 		$24K Buy
5,207
+2,265
+77% +$11.1K ﹤0.01% 1233
2015
Q4 		$19K Buy
2,942
+117
+4% +$949 ﹤0.01% 1373
2015
Q3 		$25K Buy
2,825
+2,165
+328% +$22.7K ﹤0.01% 1561
2015
Q2 		$8K Sell
660
-743
-53% -$10.3K ﹤0.01% 2933
2015
Q1 		$20K Buy
1,403
+239
+21% +$3.66K ﹤0.01% 2262
2014
Q4 		$20K Sell
1,164
-1,584
-58% -$22.8K ﹤0.01% 1609
2014
Q3 		$34K Buy
2,748
+424
+18% +$5.22K ﹤0.01% 1871
2014
Q2 		$34K Buy
+2,324
New +$35.6K ﹤0.01% 1526
2014
Q1 		– Sell
-1,470
Closed -$29K – 5161
2013
Q4 		$29K Buy
+1,470
New +$39.2K ﹤0.01% 1935
2013
Q3 		– Sell
-470
Closed -$12K – 4978
2013
Q2 		$12K Buy
+470
New +$7.49K ﹤0.01% 2225

Other funds holding STML

EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Manulife (Manufacturers Life Insurance)
Manulife (Manufacturers Life Insurance) Canada, Ontario, Canada $116B AUM 26.37% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
PC
Polar Capital London, United Kingdom $13.5B AUM 55.9% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

Tower Research Capital (TRC)'s STML Position: Q4 2019 in Review

Tower Research Capital (TRC) sold out of Stemline Therapeutics, Inc. (STML) in Q4 2019, closing a stake of 7,115 shares — an estimated $74K sold.

Tower Research Capital (TRC) first reported a position in STML in Q2 2013 and held it in 20 quarters. The position peaked at $74K in Q3 2019. 99 funds tracked by Wall St. Rank hold STML as of Q4 2019.

  • Tower Research Capital (TRC) reported no remaining Stemline Therapeutics, Inc. position as of Q4 2019 after selling out during the quarter.
  • Tower Research Capital (TRC) sold 7,115 Stemline Therapeutics, Inc. shares in Q4 2019, an estimated $74K.
  • Tower Research Capital (TRC) first reported a position in Stemline Therapeutics, Inc. in Q2 2013 and held it in 20 quarters.
  • Tower Research Capital (TRC)'s Stemline Therapeutics, Inc. position peaked at $74K in Q3 2019.
  • 99 funds tracked by Wall St. Rank held Stemline Therapeutics, Inc. as of Q4 2019.

Based on Tower Research Capital (TRC)'s 13F filing for Q4 2019, filed 7 Feb 2020.